New research suggests that patients who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on lost weight at a significantly accelerated pace than those who halt traditional diet and exercise regimens.
Findings released in a prominent medical journal demonstrates that while obese people often shed substantial amounts of their total mass while undergoing treatment, the mass returns at an average rate of 0.8 kg per month once they quit.
"Individuals buying such treatments need to be cognizant of the danger of quick weight regain when the medication is stopped," stated researcher Dr. Susan Jebb.
That rate of regain implies a return to starting weight within about a year and a half.
Weighing Approaches
The study, which looked at 37 of trials involving thousands of participants, compared the results of these new drugs with conventional dieting.
The team note that people who lose weight through diet and exercise typically have a slower creep back—perhaps 100 grams monthly—once they finish.
The Reason for the Quick Regain
Experts suggest the mechanism of the jabs is key to understanding the heightened regain.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates appetite.
"Sustained high doses of GLP-1 levels far above than normal might result in the system to produce less of its own natural GLP-1, and may also reduce sensitivity to its actions," noted Dr. Adam Collins, a dietetics expert.
"Withdrawal of this medication leads to hunger is no longer kept in check, making binge eating much more probable."
A Lifelong Condition?
Health authorities advise the jabs for individuals with obesity-related health risks, accompanied by prescribed lifestyle changes.
A number of clinicians argue that, due to the significant potential of relapse, the treatment might need to be life-long.
This perspective is echoed by drug manufacturers, who state that the findings "underscore the persistent character of obesity," similar to managing diseases like hypertension.
User Experiences
Individuals who have stopped the medication describe a intense return of cravings.
"It was like a trigger flipping and I was suddenly ravenous," recalled an individual.
This difficulty is compounded if individuals have not established sustainable dietary or behavioural modifications during therapy.
Growing Interest
Survey data indicate that a significant number of adults in the UK have tried these injections in the last 12 months, with interest remaining high.
- Use is greater among women compared to men.
- The middle-aged demographic shows the greatest level of interest.
- Many obtain the drugs through private healthcare rather than the NHS.
Ultimately, clinicians caution that while the jabs are potent tools for shedding pounds, they are not a standalone fix and long-term success relies on ongoing lifestyle changes.
